| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Alkermes) ALK4230-A101 | A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Hirte, Dr Hal | Open to recruitment | NCT02799095 |
| (BI) 1381.1 / REFMAL 473 | An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours | Hirte, Dr Hal | Open to recruitment | NCT02952248 |
| (BMS) CA209848 / CheckMate 848 | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | Hotte, Dr Sebastien | Open to recruitment | NCT03668119 |
| (CCTG) IND.228 | A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours | Hirte, Dr Hal | Open to recruitment | NCT02879162 |
| (Fusion) FPX-01-01 | A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumours | Juergens, Dr Rosalyn | Open to recruitment | NCT03746431 |
| (CCTG) IND.235 / CRI-CCTG-0001 / NIMBLe | A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay | Hirte, Dr Hal | Suspended/On hold | NCT03461952 |
Find a Trial
Contact Us